Vertex Pharmaceuticals Inc. diskutieren
Vertex Pharmaceuticals Inc.
WKN: 882807 / Symbol: VRTX / Name: Vertex / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
385,20 €
1,11 %
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $480.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Guggenheim from $450.00 to $558.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $550.00 price target on the stock, up previously from $508.00.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JPMorgan Chase & Co. from $505.00 to $510.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $500.00 to $550.00. They now have an "outperform" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at HC Wainwright from $500.00 to $600.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $480.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Bank of America Co. from $550.00 to $541.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Der Beitrag wird untersucht
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at UBS Group AG from $477.00 to $562.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $600.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $550.00 to $540.00. They now have an "outperform" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $510.00 to $503.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $480.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at UBS Group AG from $562.00 to $586.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $575.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $550.00 price target on the stock, up previously from $500.00.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Bank of America Co. from $545.00 to $522.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at HC Wainwright from $600.00 to $535.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at BMO Capital Markets from $566.00 to $520.00. They now have an "outperform" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Neueste Beiträge
Morgan_Stanley in Hasbro Inc. diskutieren